<DOC>
	<DOCNO>NCT02360514</DOCNO>
	<brief_summary>This study aim evaluate long-term immunity response neutralize antibody test adult high risk population HFRS .</brief_summary>
	<brief_title>Study Evalutate Long-term Immunity Hantavax High Risk Population HFRS</brief_title>
	<detailed_description>This clinical trial design multicenter , non-comparable , open-label clinical trial.This trial conduct write informed consent form voluntary agreement , negative result hantaanvirus antubidy neutralizaing antibody test , test drug administrate 0 , 1 , 13 month accord drug label . For antibody test , Sampling conduct pre-dose ( T0 ) , 1 month vaccination ( T1 ) , 1 year vaccination ( booster vaccination , T2 ) 1 month vaccination ( T3 ) . Also , 1 month vaccination ( T3 ) completion booster vaccination antibody retension duration observe subject antibody conduct three-year follow-up survey conduct , antibody test every year.In conclusion , sample conduct 12 month ( T4 ) , 24 month ( T5 ) , 36months ( T6 ) booster vaccionation . However , follow-up survey terminate antibody titer determine negative neutralizing antibody test fluorescent antibody technique .</detailed_description>
	<mesh_term>Hemorrhagic Fever Renal Syndrome</mesh_term>
	<criteria>The subject vaccination history ah time screen The subject whose Hantaan virus virus 's antibody show negative use Neutralizing antibody test time screen The subject history hemorrhagic fever renal syndrome The subject fever significant dystrophy</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>